Sellas Life Sciences Group Inc (SLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sellas Life Sciences Group Inc (SLS) has a cash flow conversion efficiency ratio of -0.055x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.59 Million) by net assets ($137.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Sellas Life Sciences Group Inc market cap and net worth for the company's overall valuation and market capitalisation.
Sellas Life Sciences Group Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Sellas Life Sciences Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sellas Life Sciences Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sellas Life Sciences Group Inc ranked by their cash flow conversion efficiency. Explore Sellas Life Sciences Group Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Douzone Bizon Co Ltd
KO:012510
|
0.036x |
|
Cadeler A/S
NYSE:CDLR
|
0.025x |
|
Oyak Cimento Fabrikalari AS
IS:OYAKC
|
0.075x |
|
China Science Publishing & Media Ltd
SHG:601858
|
0.023x |
|
ShenZhen QiangRui Precision Technology Co. Ltd.
SHE:301128
|
0.008x |
|
Wisdom Marine Lines Co Ltd
TW:2637
|
0.055x |
|
Zhejiang Changsheng Sliding Bearings Co Ltd Class A
SHE:300718
|
0.042x |
|
Hangzhou Robam Appliances Co Ltd
SHE:002508
|
0.022x |
Annual Cash Flow Conversion Efficiency for Sellas Life Sciences Group Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Sellas Life Sciences Group Inc from 2007 to 2025. View SLS live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $70.87 Million | $-28.39 Million | -0.401x | +89.29% |
| 2024-12-31 | $9.46 Million | $-35.40 Million | -3.740x | -194.98% |
| 2023-12-31 | $-7.98 Million | $-31.41 Million | 3.938x | +180.24% |
| 2022-12-31 | $4.85 Million | $-23.81 Million | -4.908x | -283.78% |
| 2021-12-31 | $20.35 Million | $-26.02 Million | -1.279x | -243.27% |
| 2020-12-31 | $27.96 Million | $-10.42 Million | -0.373x | +87.13% |
| 2019-12-31 | $6.09 Million | $-17.64 Million | -2.896x | +50.08% |
| 2018-12-31 | $5.25 Million | $-30.42 Million | -5.800x | -9.26% |
| 2017-12-31 | $2.07 Million | $-10.99 Million | -5.309x | -238.71% |
| 2016-12-31 | $28.66 Million | $-44.91 Million | -1.567x | +56.02% |
| 2015-12-31 | $13.51 Million | $-48.16 Million | -3.564x | -208.10% |
| 2014-12-31 | $37.06 Million | $-42.87 Million | -1.157x | +76.45% |
| 2013-12-31 | $5.89 Million | $-28.91 Million | -4.911x | -550.28% |
| 2012-12-31 | $27.76 Million | $-20.96 Million | -0.755x | +47.93% |
| 2011-12-31 | $10.11 Million | $-14.67 Million | -1.451x | +65.63% |
| 2010-12-31 | $2.43 Million | $-10.26 Million | -4.221x | +73.42% |
| 2009-12-31 | $741.00K | $-11.77 Million | -15.883x | -1410.61% |
| 2008-12-31 | $8.97 Million | $-9.43 Million | -1.051x | -88.18% |
| 2007-12-31 | $10.82 Million | $-6.05 Million | -0.559x | -- |
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or … Read more